Mitoten 2.5 mg is a chemotherapy medication primarily used in the treatment of adrenocortical carcinoma (a rare cancer of the adrenal gland). Its active ingredient is Mitotane, which belongs to the adrenolytic and cytotoxic drug class. Mitoten works by selectively targeting adrenal cortical cells, reducing tumor growth and excess hormone production associated with adrenal cancers.

Mechanism of Action

• Mitotane causes selective cytotoxicity to adrenal cortical cells, leading to cell death.

• It interferes with steroid synthesis enzymes in the adrenal cortex, reducing the production of cortisol and other adrenal hormones.

• This dual action helps control both tumor growth and hormone overproduction, such as in Cushing’s syndrome caused by adrenal carcinoma.

  Uses

  • Treatment of adrenocortical carcinoma (primary use).

  • Management of hormone excess (Cushing’s syndrome) associated with adrenal tumors.

  • Sometimes used post-surgery to reduce the risk of tumor recurrence.

    Adverse Effects

    • Nausea, vomiting, loss of appetite

    • Fatigue, dizziness, or lethargy

    • Gastrointestinal disturbances (diarrhea, abdominal pain)

    • Changes in liver function tests